Hello, everyone, and welcome to Allurion fourth quarter earnings call. Please note that this call is being recorded. After the speaker's prepared remarks, there will be a question and answer session.

Allurion Technologies' gastric balloon and Novo Nordisk's semaglutide achieved 20.3% weight loss in a trial. Read more here.

Chardan notes that Allurion has announced additional data evaluating the use of its Allurion Balloon in combination with patients be treated ...

Roth MKM keeps a Buy rating and $16 price target on Allurion Technologies (ALUR) after its initial results from Allurion Program-GLP-1 combo.

Allurion Technologies (NYSE:ALUR – Get Free Report) is anticipated to release its earnings data before the market opens on ...

The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrating improved long-term tolerability and adherence to GLP-1 therapy. Previous ...

These patents, both of which are scheduled to issue on March 11, 2025, provide additional claims for an enhanced, next-generation version of Allurion’s proprietary Balloon technology for the ...

The Allurion Program includes a swallowable gastric balloon, which is part of a broader weight-loss platform that also features virtual care and a behavior change program. With revenue of $34.75 ...